Immune phenotypes that are associated with subsequent COVID-19 severity inferred from post-recovery samples

Thomas Liechti; Yaser Iftikhar; Massimo Mangino; Margaret Beddall; Charles W. Goss; Jane A. O’Halloran; Philip A. Mudd; Mario Roederer

doi:10.1038/s41467-022-34638-2

Nature Communications (Nov 2022)

Immune phenotypes that are associated with subsequent COVID-19 severity inferred from post-recovery samples

Thomas Liechti,
Yaser Iftikhar,
Massimo Mangino,
Margaret Beddall,
Charles W. Goss,
Jane A. O’Halloran,
Philip A. Mudd,
Mario Roederer

Affiliations

Thomas Liechti: ImmunoTechnology Section, Vaccine Research Center, NIAID, NIH
Yaser Iftikhar: ImmunoTechnology Section, Vaccine Research Center, NIAID, NIH
Massimo Mangino: Department of Twin Research & Genetic Epidemiology, King’s College of London
Margaret Beddall: ImmunoTechnology Section, Vaccine Research Center, NIAID, NIH
Charles W. Goss: Division of Biostatistics, Washington University School of Medicine
Jane A. O’Halloran: Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine
Philip A. Mudd: Department of Emergency Medicine, Washington University School of Medicine
Mario Roederer: ImmunoTechnology Section, Vaccine Research Center, NIAID, NIH

DOI: https://doi.org/10.1038/s41467-022-34638-2
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 17

Abstract

Read online

The association of specific immune cell types with SARS-CoV-2 severity is not fully understood. Here the authors analyse PBMC from individuals recovered from COVID-19 and propose immune cell signatures post recovery that are associated with disease severity.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal